A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT03693300
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
117
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
Durvalumab
Sponsor
AstraZeneca